Holen Sie sich die Stockscreener-App
19.75
3.80%
0.826
Schlusskurs vom Vortag:
$18.92
Offen:
$18.4
24-Stunden-Volumen:
1.18M
Relative Volume:
0.45
Marktkapitalisierung:
$15.29B
Einnahmen:
$220.00K
Nettoeinkommen (Verlust:
$-1.08B
KGV:
-13.67
EPS:
-1.4448
Netto-Cashflow:
$-326.53M
1W Leistung:
+13.78%
1M Leistung:
+21.30%
6M Leistung:
-5.90%
1J Leistung:
-4.01%
1-Tages-Spanne:
$18.40
$19.85
1-Wochen-Bereich:
$16.38
$19.85
52-Wochen-Spanne:
$13.83
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
19.72 | 14.67B | 220.00K | -1.08B | -326.53M | -1.4448 |
VRTX
Vertex Pharmaceuticals Inc
|
441.29 | 113.62B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.74 | 82.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
744.42 | 46.12B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.64 | 43.60B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
158.88 | 35.54B | 606.42M | -1.28B | -997.58M | -6.403 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2025-12-17 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-17 | Eingeleitet | Barclays | Underweight |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Neutral |
| 2025-07-01 | Eingeleitet | UBS | Buy |
| 2025-06-11 | Eingeleitet | Leerink Partners | Underperform |
| 2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | Goldman | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-07 | Eingeleitet | Citigroup | Buy |
| 2024-03-26 | Eingeleitet | Stifel | Buy |
| 2018-06-28 | Herabstufung | Janney | Buy → Neutral |
| 2018-05-02 | Eingeleitet | Janney | Buy |
| 2018-04-12 | Bestätigt | Needham | Buy |
| 2018-02-13 | Eingeleitet | BTIG Research | Buy |
| 2018-01-04 | Eingeleitet | SunTrust | Buy |
| 2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-05 | Bestätigt | Needham | Buy |
| 2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-30 | Eingeleitet | Needham | Buy |
| 2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
Wells Fargo Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Assenagon Asset Management S.A. Invests $1.04 Million in Summit Therapeutics PLC $SMMT - marketbeat.com
$Summit Therapeutics (SMMT.US)$ - Moomoo
Summit Therapeutics PLC (NASDAQ:SMMT) Given Average Recommendation of "Moderate Buy" by Analysts - marketbeat.com
Aug Retail: Is Summit Therapeutics Inc undervalued by DCF analysisGap Down & Weekly Sector Rotation Insights - baoquankhu1.vn
Revolution Medicines and Summit Therapeutics Advance Broad RAS(ON) Combo Study in Solid Tumors - TipRanks
Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Maintains Target Price $18 - Moomoo
What makes Summit Therapeutics (SMMT) one of the best large caps under $30 - MSN
Summit Therapeutics Links Ivonescimab Brain Metastases Data To November PDUFA - Sahm
Summit Therapeutics stock drops 3.94% as FDA accepts BLA for Ivonescimab in NSCLC - Traders Union
A Look At Summit Therapeutics (SMMT) Valuation After New Ivonescimab Phase III Data And FDA BLA Filing - Yahoo Finance
Summit Therapeutics (SMMT) Is Up 6.9% After Phase III Ivonescimab Data And FDA FilingWhat's Changed - Yahoo Finance
Summit Therapeutics (SMMT) climbs 15.4% ahead of pipeline Q2 updates - msn.com
Summit Therapeutics outlines ivonescimab progress with key Phase III data expected mid-2025 - MSN
Summit Therapeutics to present ivonescimab data at ELCC 2026 - StreetInsider
Summit Therapeutics Inc. Announces Multiple Ivonescimab Data Sets from Phase III Studies in Advanced Nsclc Patient Populations to Be Featured At ELCC 2026 - MarketScreener
Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026 - Business Wire
SMMT Stock Price, Quote & Chart | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Summit Therapeutics (NASDAQ:SMMT) Raised to Strong-Buy at Truist Financial - marketbeat.com
What Makes Summit Therapeutics (SMMT) One of the Best Large Caps Under $30 - Insider Monkey
Aug Sectors: Can Summit Therapeutics Inc be the next market leader - baoquankhu1.vn
5 Large Cap Stocks Under $30 With Huge Upside Potential - Insider Monkey
Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates - Insider Monkey
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - Yahoo Finance
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - The Motley Fool
U.S. Markets Rose Wednesday; Summit Therapeutics Topped Leaders - Barron's
Summit Therapeutics Enters Strong Growth Phase Amid Partnerships and Trials - StocksToTrade
Summit Therapeutics (NASDAQ:SMMT) Trading 12.1% HigherHere's What Happened - marketbeat.com
Summit Therapeutics Inc. (SMMT) focused on non-small cell lung cancer trial of Ivonescimab - MSN
Axsome Therapeutics faces competition amid FDA review risk for Summit's ivonescimab - Intellectia AI
Summit Therapeutics (SMMT) Stock Price Prediction for 2026, 2030-2040 - Traders Union
347,241 Shares in Summit Therapeutics PLC $SMMT Acquired by Tudor Investment Corp ET AL - marketbeat.com
Responsive Playbooks and the SMMT Inflection - Stock Traders Daily
Trade Recap: Does Summit Therapeutics Inc have a sustainable dividend2026 Investor Takeaways & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Analysts Are Bullish on Top Healthcare Stocks: Scholar Rock Holding (SRRK), Summit Therapeutics (SMMT) - The Globe and Mail
SMMT PE Ratio & Valuation, Is SMMT Overvalued - Intellectia AI
Summit Therapeutics Inc.Common Stock (NQ: SMMT - FinancialContent
Jefferies downgrades Summit Therapeutics (SMMT) - MSN
Should Jefferies’ Downgrade and Ivonesimab Focus Shape Summit Therapeutics’ (SMMT) Risk‑Reward Profile? - simplywall.st
SMMT Downgraded by Jefferies, Price Target Slashed by 64% | SMMT Stock News - GuruFocus
Summit Therapeutics (NASDAQ:SMMT) Rating Lowered to "Hold" at Jefferies Financial Group - MarketBeat
Summit Therapeutics downgraded to Hold from Buy at Jefferies - TipRanks
SMMT SEC FilingsSummit Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Summit Therapeutics (NASDAQ:SMMT) Trading 6.5% HigherTime to Buy? - MarketBeat
How correlated is Summit Therapeutics Inc to the S P5002026 Chart Watch & Advanced Technical Signal Analysis - baoquankhu1.vn
WINTON GROUP Ltd Makes New Investment in Summit Therapeutics PLC $SMMT - MarketBeat
Understanding the Setup: (SMMT) and Scalable Risk - Stock Traders Daily
Summit Therapeutics at The Citizens Life Sciences Conference: Strategic Insights on Ivonescimab - Investing.com Nigeria
Earnings Report: Is Summit Therapeutics Inc impacted by rising ratesQuarterly Portfolio Review & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Earnings Recap: How correlated is Summit Therapeutics Inc to the S P5002026 Outlook & Reliable Entry Point Alerts - baoquankhu1.vn
Summit Therapeutics’ Earnings Call Highlights OS Hurdles - The Globe and Mail
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Summit Therapeutics Inc-Aktie (SMMT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
1.34%
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):